DHRS2

Across TCGA pan-cancer cohorts, DHRS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DHRS2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DHRS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DHRS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where DHRS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.779	0.931	.008	19	view →
LUAD	DFS	Tertile	All	0.362	0.821	.016	16	view →
LSCC	OS	Median	III,IV	0.498	1.000	.029	4	view →
HNSC	OS	Median	III,IV	0.943	0.787	.021	3	view →
CCRCC	DFS	Quartile	All	1.000	0.192	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DHRS2–PDAC (OS)

Open the PDAC breakdown →